Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide

Hopkins Ashley M.; Vitry Agnes I.; ODoherty Catherine E.; Proudman Susanna M.; Wiese Michael D.

首页> 外文期刊>International journal of rheumatic diseases >Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide

【24h】

Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide

机译：澳大利亚药物效益方案的变化对生物疾病改性的抗抗肠药物的限制影响了莱夫洛胺的使用

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《International journal of rheumatic diseases》 |2017年第11期|共3页
作者
Hopkins Ashley M.; Vitry Agnes I.; ODoherty Catherine E.; Proudman Susanna M.; Wiese Michael D.;
展开▼
作者单位

Sansom Institute for Health ResearchSchool of Pharmacy and Medical SciencesAdelaide South Australia;

Sansom Institute for Health ResearchSchool of Pharmacy and Medical SciencesAdelaide South Australia;

Sansom Institute for Health ResearchSchool of Pharmacy and Medical SciencesAdelaide South Australia;

Department of RheumatologyRoyal Adelaide HospitalAdelaide South Australia Australia;

Sansom Institute for Health ResearchSchool of Pharmacy and Medical SciencesAdelaide South Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类全身性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide [J] . Hopkins Ashley M., Vitry Agnes I., ODoherty Catherine E., International journal of rheumatic diseases . 2017,第Suppla1期

机译：澳大利亚药物效益方案的变化对生物疾病改性的抗抗肠药物的限制影响了莱夫洛胺的使用
2. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme? [J] . Lu CY, Williams KM, Day RO Internal medicine journal . 2007,第9期

机译：通过药物益处方案对高成本生物制剂的控制获取来改变疾病修饰的抗风湿药物吗？
3. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing [J] . Pontifex Eliza K., Dissanayake Kokum, Bursill David, International journal of rheumatic diseases . 2019,第2期

机译：澳大利亚人工症关节炎患者最小疾病活动的患病率：评估生物疾病改性抗胃部药物规定的国家资金标准的结果
4. What Makes Diseases and Drug Research and Development Attractive for the Pharmaceutical Industry [C] . Nicola Hanekom, Louzanne Bam, Imke de Kock IEEE International Conference on Engineering, Technology and Innovation . 2019

机译：是什么使疾病和药物研发对制药行业具有吸引力
5. The impact of pharmacy benefit design changes on medication adherence and generic drug utilization among commercially insured continuously enrolled patients with chronic diseases. [D] . Su, Weiping. 2015

机译：药房福利设计变更对持续参加商业保险的慢性病患者的药物依从性和通用药物利用的影响。
6. Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria [O] . Konstantin Tachkov, Zornitsa Mitkova, Vladimira Boyadzieva, 2021

机译：生物仿制性引入是否影响了他们的价格和利用？保加利亚生物疾病（BDMARD）生物疾病改性的病例
7. Changes in health related quality of life for arthritis patients taking biological disease modifying antirheumatic drugs : data from the Australian Rheumatology Association database [O] . Staples, M., Oldroyd, J ., Murphy, B., 2009

机译：服用生物病抗风湿药的关节炎患者的健康相关生活质量变化：来自澳大利亚风湿病协会数据库的数据

Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide

著录项

引文网络

相似文献

相关主题

期刊订阅